

# Andrea Flynn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4962884/publications.pdf>

Version: 2024-02-01

18  
papers

181  
citations

1306789

7  
h-index

1199166

12  
g-index

21  
all docs

21  
docs citations

21  
times ranked

283  
citing authors

#	ARTICLE	IF	CITATIONS
1	Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. <i>Neuro-Oncology</i> , 2022, 24, 1366-1374.	0.6	36
2	Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma. <i>Current Oncology Reports</i> , 2020, 22, 19.	1.8	35
3	Myc, Oncogenic Protein Translation, and the Role of Polyamines. <i>Medical Sciences (Basel)</i> , 2021, 10, 1078-1088.	1.3	28
4	Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 6266-6276.	3.2	26
5	A novel ATXN1-DUX4 fusion expands the spectrum of CIC-rearranged sarcoma™ of the CNS to include non-CIC alterations. <i>Acta Neuropathologica</i> , 2021, 141, 619-622.	3.9	16
6	Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 555-562.	1.1	15
7	Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice. <i>Leukemia and Lymphoma</i> , 2021, 62, 1990-1994.	0.6	9
8	Severe Mucho-Habermann-Like Ulceronecrotic Skin Disease in Cell Acute Lymphoblastic Leukemia Responsive to Basiliximab and Stem Cell Transplant. <i>Pediatric Dermatology</i> , 2017, 34, e265-e270.	0.5	6
9	Evolving paradigms for new agent development in pediatric oncology. <i>Current Opinion in Pediatrics</i> , 2018, 30, 10-16.	1.0	3
10	FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS10056-TPS10056.	0.8	3
11	NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 10558-10558.	0.8	3
12	Targeted agents recommended by the CNS TAP tool compared to those selected by a tumor board in a molecularly-driven clinical trial in children and young adults with DIPG. <i>Journal of Clinical Oncology</i> , 2021, 39, 2048-2048.	0.8	0
13	Serial plasma and CSF cell-free tumor DNA (cf-tDNA) tracking in diffuse midline glioma patients undergoing treatment with ONC201. <i>Journal of Clinical Oncology</i> , 2021, 39, 2012-2012.	0.8	0
14	EPCT-03. SERIAL PLASMA AND CSF CELL-FREE TUMOR DNA (CF-TDNA) TRACKING IN DIFFUSE MIDLINE GLIOMA PATIENTS UNDERGOING TREATMENT WITH ONC201. <i>Neuro-Oncology</i> , 2021, 23, i46-i47.	0.6	0
15	INN-16. CNS-TAP TOOL RECOMMENDATIONS OF TARGETED ANTI-CANCER AGENTS COMPARED TO THOSE SELECTED BY A MULTIDISCIPLINARY TUMOR BOARD IN A MOLECULARLY-DRIVEN DIPG CLINICAL TRIAL (PNOC003). <i>Neuro-Oncology</i> , 2021, 23, vi108-vi108.	0.6	0
16	CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii45-ii46.	0.6	0
17	BIOM-28. SERIAL PLASMA AND CSF CELL-FREE TUMOR DNA (cf-tDNA) TRACKING IN DIFFUSE MIDLINE GLIOMA PATIENTS UNDERGOING TREATMENT WITH ONC201. <i>Neuro-Oncology</i> , 2021, 23, vi16-vi17.	0.6	0
18	DIPG-49. International preclinical drug discovery and biomarker program informing an adoptive combinatorial trial for DMG. <i>Neuro-Oncology</i> , 2022, 24, i29-i30.	0.6	0